Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI)CESS studies.

BACKGROUND Tumor volumes of more than 100 ml and the presence of primary metastases have been identified as determinants of poor prognosis in patients with Ewing tumors. We sought to assess the prevalence of critical tumor size and primary metastases in a large national sample of patients at the time of first diagnosis and to identify factors that are associated with their occurrence. PATIENTS The present report is based on data of 945 German patients who were enrolled into the (EI)CESS therapy studies between 1980 and 1997. It is assumed that registration of German patients with Ewing tumors under the age of 15 years was almost complete since around 1985. Diagnoses of primary tumors were ascertained exclusively by biopsies. Analyses were restricted to patients with Ewing tumors of bone due to the few occurrences in soft tissues. METHODS Tumor volume data as assessed by radiography, computed tomography or nuclear magnetic imaging were available for 821 patients. The diagnosis of primary metastases was based on thoracic computed tomography or on whole body bone scans in 936 patients. Suspicious lesions had to be confirmed by bone marrow biopsies. We explored how year of first diagnosis, age at first diagnosis, sex, histological subtype and site of the primary tumor related to tumor size and presence of metastases by univariate and multivariate statistical techniques. RESULTS Sixty-eight percent of the patients (n = 559) had a volume above 100 ml with smaller tumors being more common in childhood than in late adolescence and early adulthood. Extensive volumes were observed in almost 90% of the tumors located in femur and pelvis while they were less common in other sites (P < 0.001). On average, 26% of all patients presented with clinically apparent primary metastases. The detection rate of metastases was markedly higher in patients diagnosed after 1991 (P < 0.001). Primary metastases were also significantly more common for tumors originating in the pelvis and for peripheral neuroectodermal tumors (PNET; P < 0.01). Tumors greater than 100 ml were positively associated with metastatic disease (P < 0.001). Multivariate analyses, which included simultaneously all univariate predictors in a logistic regression model, indicated that most of the observed associations were essentially unconfounded. The adjusted odds ratios (OR) for the presence of tumor volumes > or = 100 ml were OR = 1.5 per age rise of 10 years, and OR = 5.8 for pelvis and OR = 7.1 for femur as primary tumor site (all P < 0.001). The presence of metastases was significantly associated with the year of diagnosis (OR = 1.9, after 1991 vs. before 1986), pelvis as site of the primary tumor (OR = 1.8), a PNET (OR = 1.5), and tumor size > or = 100 ml (OR = 1.6). CONCLUSIONS In conclusion, we find that the prevalence of established factors for an unfavorable prognosis is disturbingly high among patients diagnosed with Ewing tumors. Recent progress in imaging techniques seems to account for much of the rise in the detection rate of metastases after 1991. We identify age and, in particular pelvic and femoral site as the major determinants of local tumor extension. Occurrence of primary metastases is independently related to tumor size, pelvic site, and PNET.

[1]  J. Ewing Diffuse endothelioma of bone , 1972 .

[2]  H. Kovar,et al.  Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. , 1998, Current opinion in oncology.

[3]  J. Maurel,et al.  Poor prognosis Ewing's sarcoma and peripheral primitive neuroectodermal tumours (PNET). , 1996, Cancer treatment reviews.

[4]  M. Neves,et al.  Ewing's sarcoma in children: Twenty‐five years of experience at the institute portuagěs de oncologia de francisco gentil (I.P.O.F.G.) , 1991, Journal of surgical oncology.

[5]  W. Winkelmann,et al.  Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  U. Göbel,et al.  Die GPO cooperativen Ewing-Sarkom Studien CESS 81/86: , 1988 .

[7]  W. Winkelmann,et al.  Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. , 1995, International journal of radiation oncology, biology, physics.

[8]  W. Winkelmann,et al.  Radiation therapy as local treatment in ewing's sarcoma. Results of the cooperative ewing's sarcoma studies cess 81 and cess 86 , 1991, Cancer.

[9]  K. Cooper,et al.  A clinicopathologic study of 20 cases of large‐cell (atypical) Ewing's sarcoma of bone , 1980, The American journal of surgical pathology.

[10]  D. Harms,et al.  Malignant peripheral neuroectodermal tumor and its necessary distinction from ewing's Sarcoma. A report from the kiel pediatric tumor registry , 1991, Cancer.

[11]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[12]  W. Winkelmann,et al.  Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: The CESS 86 experience , 1999 .

[13]  J. Michaelis,et al.  Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. , 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  W. Winkelmann,et al.  Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Bernard,et al.  Childhood cancer incidence in the south-east of France. A report of the Provence-Alpes-Côte d'Azur and Corsica Regions Pediatric Cancer Registry, 1984-1991. , 1993, European journal of cancer.

[16]  H Kovar,et al.  MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration , 1991, Cancer.

[17]  D. Parkin,et al.  International variations in the incidence of childhood bone tumours , 1993, International journal of cancer.

[18]  G COOPER,et al.  Bone cancer. , 1951, Virginia medical monthly.

[19]  T. Triche,et al.  Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis? , 1995, European journal of cancer.

[20]  Leif Bjermer,et al.  Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross-country skiers , 2010, British Journal of Sports Medicine.

[21]  W. Winkelmann,et al.  Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6‐year experience of a European cooperative trial , 1988, Cancer.

[22]  H. Grier The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. , 1997, Pediatric clinics of North America.

[23]  D. Parkin,et al.  Geographic and ethnic variations in the incidence of childhood cancer. , 1996, British medical bulletin.

[24]  Dehner Lp NEUROEPITHELIOMA (PRIMITIVE NEUROECTODERMAL TUMOR) AND EWING'S SARCOMA : AT LEAST A PARTIAL CONSENSUS , 1994 .

[25]  T. Kinsella,et al.  Prognostic value of histopathology in ewing's sarcoma. Long‐term follow‐up of distal extremity primary tumors , 1991, Cancer.

[26]  H. Jürgens,et al.  Deskriptive Epidemiologie der Ewing-Tumoren - Analysen der deutschen Patienten von (EI) CESS 1980-1997* , 1999 .

[27]  L. Dehner Neuroepithelioma (primitive neuroectodermal tumor) and Ewing's sarcoma. At least a partial consensus. , 1994, Archives of pathology & laboratory medicine.